INCY up +0.65% percent Today $INCY High is at 70.4
Post# of 91
Posted On: 11/19/2014 12:40:06 PM
INCY up +0.65% percent Today $INCY High is at 70.43 and the Low 69.28 with current volume of 160,279.
Recent News posted below.
Incyte Corp INCY other info.
http://investorshangout.com/Incyte-Corporation-INCY-54453/
INCY Incyte Corp Recent Headline News
Incyte Earnings Hindsight: Up 8.4% in Last 18 Days (INCY)
Comtex SmarTrend(R) - Mon Nov 17, 4:10PM CST
When Incyte (NASDAQ:INCY) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.09 on sales of $149.9 million. Incyte actually reported earnings of $0.33 per share on sales of $198.1 million, beating EPS estimates by $0.24 and beating revenue estimates by $48.3 million. Shares of Incyte have climbed from $64.18 to $69.54, representing a gain of 8.4% since the company reported earnings 18 days ago.
INCY: 71.79 (+2.15)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.34 (-0.49), GILD: 101.98 (-1.73), GERN: 3.19 (+0.02), MRK: 59.50 (-0.39), AZN: 75.37 (+1.39), PFE: 30.32 (-0.27), INCY: 71.79 (+2.15), BMY: 58.61 (-0.09), CTIC: 2.23 (-0.05), NVS: 95.80 (+0.22)
Incyte Up 36.4% Since SmarTrend Uptrend Call (INCY)
Comtex SmarTrend(R) - Mon Nov 17, 2:03PM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 1 month, Incyte has returned 36.37% as of today's recent price of $69.66.
INCY: 71.79 (+2.15)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 303.84 (-1.72), GILD: 101.98 (-1.73), INCY: 71.79 (+2.15), ALXN: 194.09 (+1.72), CELG: 107.44 (+0.66)
Incyte to Present at Upcoming Investor Conferences
Business Wire - Mon Nov 17, 7:00AM CST
Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of December:
INCY: 71.79 (+2.15)
Look for Shares of Incyte to Potentially Rebound after Yesterday's 2.35% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 4:34PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.27 to a high of $71.20. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $70.14 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 71.79 (+2.15)
Incyte Falls 2.35% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 14, 4:34PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.27 to a high of $71.20. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $70.14 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 71.79 (+2.15)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.50 (-0.39), INCY: 71.79 (+2.15), CLDX: 19.14 (+1.42), NLNK: 32.51 (-0.15), GSK: 46.33 (+0.05), BMY: 58.61 (-0.09), SRNE: 3.97 (-0.03)
Watch for Incyte to Potentially Pullback After Gaining 2.37% Yesterday
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.79 (+2.15)
SmarTrend Watching for Potential Pullback in Shares of Incyte After 2.37% Gain
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.79 (+2.15)
Incyte Earnings Review: 11 Days after Announcement Shares Up 8.0% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 1:34PM CST
A week ago on October 30th, 2014 Incyte (NASDAQ:INCY) reported earnings and analysts, on average, expected earnings of $0.09 on sales of $149.9 million. Incyte actually reported earnings of $0.33 per share on sales of $198.1 million, beating EPS estimates by $0.24 and beating revenue estimates by $48.3 million. Shares of Incyte have climbed from $64.18 to $69.32, representing a gain of 8.0% since the company reported earnings 11 days ago.
INCY: 71.79 (+2.15)
Uptrend Call Working As Incyte Stock Rises 35.6% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 10:48AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 3 weeks, Incyte has returned 35.57% as of today's recent price of $69.25.
INCY: 71.79 (+2.15)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.34 (+0.06), PCYC: 138.65 (+1.58), CLDX: 19.14 (+1.42), INCY: 71.79 (+2.15), BIND: 8.48 (-2.07), CELG: 107.44 (+0.66), OMER: 21.50 (+0.10), VSTM: 9.01 (+0.04), GILD: 101.98 (-1.73), OGXI: 2.12 (-0.02), ANTH: 1.82 (-0.01), NVAX: 4.96 (-0.05)
After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 3.19 (+0.02), INCY: 71.79 (+2.15)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.32 (-0.27), INCY: 71.79 (+2.15), ONTX: 4.90 (+0.05), BMY: 58.61 (-0.09), GSK: 46.33 (+0.05), STML: 14.13 (+0.07), SNTA: 3.15 (-0.05), KBIO: 1.98 (+0.01), BPTH: 2.89 (-0.01), CELGZ: 3.20 (+0.08), NVS: 95.80 (+0.22)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.40 (-0.28), BCR: 166.19 (-1.17), INCY: 71.79 (+2.15), MYL: 55.66 (-0.58), AEGR: 21.11 (+0.62)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 91.09 (+1.14), CYTX: 0.41 (-0.03), ACHN: 13.28 (-0.03), INCY: 71.79 (+2.15), SRPT: 15.84 (+0.27)
30.9% Return Seen to Date on SmarTrend Incyte Call (INCY)
Comtex SmarTrend(R) - Mon Nov 03, 9:21AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 weeks, Incyte has returned 30.87% as of today's recent price of $66.85.
INCY: 71.79 (+2.15)
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 303.84 (-1.72), INCY: 71.79 (+2.15), LLY: 67.33 (-0.45), NVS: 95.80 (+0.22)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 109.09 (+0.97), BIIB: 303.84 (-1.72), INCY: 71.79 (+2.15), ILMN: 189.73 (-0.12)
Recent News posted below.
Incyte Corp INCY other info.
http://investorshangout.com/Incyte-Corporation-INCY-54453/
INCY Incyte Corp Recent Headline News
Incyte Earnings Hindsight: Up 8.4% in Last 18 Days (INCY)
Comtex SmarTrend(R) - Mon Nov 17, 4:10PM CST
When Incyte (NASDAQ:INCY) reported earnings 18 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.09 on sales of $149.9 million. Incyte actually reported earnings of $0.33 per share on sales of $198.1 million, beating EPS estimates by $0.24 and beating revenue estimates by $48.3 million. Shares of Incyte have climbed from $64.18 to $69.54, representing a gain of 8.4% since the company reported earnings 18 days ago.
INCY: 71.79 (+2.15)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.34 (-0.49), GILD: 101.98 (-1.73), GERN: 3.19 (+0.02), MRK: 59.50 (-0.39), AZN: 75.37 (+1.39), PFE: 30.32 (-0.27), INCY: 71.79 (+2.15), BMY: 58.61 (-0.09), CTIC: 2.23 (-0.05), NVS: 95.80 (+0.22)
Incyte Up 36.4% Since SmarTrend Uptrend Call (INCY)
Comtex SmarTrend(R) - Mon Nov 17, 2:03PM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 1 month, Incyte has returned 36.37% as of today's recent price of $69.66.
INCY: 71.79 (+2.15)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 303.84 (-1.72), GILD: 101.98 (-1.73), INCY: 71.79 (+2.15), ALXN: 194.09 (+1.72), CELG: 107.44 (+0.66)
Incyte to Present at Upcoming Investor Conferences
Business Wire - Mon Nov 17, 7:00AM CST
Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of December:
INCY: 71.79 (+2.15)
Look for Shares of Incyte to Potentially Rebound after Yesterday's 2.35% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 4:34PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.27 to a high of $71.20. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $70.14 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 71.79 (+2.15)
Incyte Falls 2.35% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 14, 4:34PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.27 to a high of $71.20. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $70.14 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 71.79 (+2.15)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.50 (-0.39), INCY: 71.79 (+2.15), CLDX: 19.14 (+1.42), NLNK: 32.51 (-0.15), GSK: 46.33 (+0.05), BMY: 58.61 (-0.09), SRNE: 3.97 (-0.03)
Watch for Incyte to Potentially Pullback After Gaining 2.37% Yesterday
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.79 (+2.15)
SmarTrend Watching for Potential Pullback in Shares of Incyte After 2.37% Gain
Comtex SmarTrend(R) - Mon Nov 10, 4:44PM CST
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $68.77 to a high of $71.00. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $70.67 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 71.79 (+2.15)
Incyte Earnings Review: 11 Days after Announcement Shares Up 8.0% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 1:34PM CST
A week ago on October 30th, 2014 Incyte (NASDAQ:INCY) reported earnings and analysts, on average, expected earnings of $0.09 on sales of $149.9 million. Incyte actually reported earnings of $0.33 per share on sales of $198.1 million, beating EPS estimates by $0.24 and beating revenue estimates by $48.3 million. Shares of Incyte have climbed from $64.18 to $69.32, representing a gain of 8.0% since the company reported earnings 11 days ago.
INCY: 71.79 (+2.15)
Uptrend Call Working As Incyte Stock Rises 35.6% (INCY)
Comtex SmarTrend(R) - Mon Nov 10, 10:48AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 3 weeks, Incyte has returned 35.57% as of today's recent price of $69.25.
INCY: 71.79 (+2.15)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.34 (+0.06), PCYC: 138.65 (+1.58), CLDX: 19.14 (+1.42), INCY: 71.79 (+2.15), BIND: 8.48 (-2.07), CELG: 107.44 (+0.66), OMER: 21.50 (+0.10), VSTM: 9.01 (+0.04), GILD: 101.98 (-1.73), OGXI: 2.12 (-0.02), ANTH: 1.82 (-0.01), NVAX: 4.96 (-0.05)
After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 3.19 (+0.02), INCY: 71.79 (+2.15)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 30.32 (-0.27), INCY: 71.79 (+2.15), ONTX: 4.90 (+0.05), BMY: 58.61 (-0.09), GSK: 46.33 (+0.05), STML: 14.13 (+0.07), SNTA: 3.15 (-0.05), KBIO: 1.98 (+0.01), BPTH: 2.89 (-0.01), CELGZ: 3.20 (+0.08), NVS: 95.80 (+0.22)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.40 (-0.28), BCR: 166.19 (-1.17), INCY: 71.79 (+2.15), MYL: 55.66 (-0.58), AEGR: 21.11 (+0.62)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 91.09 (+1.14), CYTX: 0.41 (-0.03), ACHN: 13.28 (-0.03), INCY: 71.79 (+2.15), SRPT: 15.84 (+0.27)
30.9% Return Seen to Date on SmarTrend Incyte Call (INCY)
Comtex SmarTrend(R) - Mon Nov 03, 9:21AM CST
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on October 17th, 2014 at $51.08. In approximately 2 weeks, Incyte has returned 30.87% as of today's recent price of $66.85.
INCY: 71.79 (+2.15)
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 303.84 (-1.72), INCY: 71.79 (+2.15), LLY: 67.33 (-0.45), NVS: 95.80 (+0.22)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 109.09 (+0.97), BIIB: 303.84 (-1.72), INCY: 71.79 (+2.15), ILMN: 189.73 (-0.12)
(0)
(0)Incyte Corporation (INCY) Stock Research Links
Scroll down for more posts ▼